Filing Details
- Accession Number:
- 0001645470-19-000039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-06-18 18:11:09
- Reporting Period:
- 2019-06-13
- Accepted Time:
- 2019-06-18 18:11:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1528172 | Endonovo Therapeutics Inc. | ENDV | Pharmaceutical Preparations (2834) | 452552528 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1645470 | Brian Alan Collier | 6320 Canoga Avenue 15Th Floor Woodland Hills CA 91367 | Ceo | No | Yes | No | No |
Transaction Summary
Purchased: | 52,000 shares | Avg. Price: $0.01 | Total Value: $635.50 |
Number of Shares After Transactions: | 24,354,097 shares |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-06-13 | 11,000 | $0.01 | 24,313,097 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-06-13 | 11,000 | $0.01 | 24,324,097 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-06-14 | 11,000 | $0.01 | 24,335,097 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-06-17 | 2,000 | $0.01 | 24,337,097 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-06-17 | 5,000 | $0.01 | 24,342,097 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-06-17 | 5,000 | $0.01 | 24,347,097 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-06-17 | 5,000 | $0.01 | 24,352,097 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-06-17 | 2,000 | $0.01 | 24,354,097 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |